多发性硬化髓鞘再生:从基础科学到临床转化
本文综述多发性硬化的髓鞘再生治疗策略。免疫治疗可控制复发缓解期疾病活动,但无法阻止进展期轴突和神经元损伤导致的残疾进展。促进髓鞘再生以恢复神经传导和代谢支持是神经保护策略,动物研究已提供干预靶点,但临床试验设计和结局测量仍存挑战。
要点
- 免疫治疗有效控制复发缓解期疾病活动,但未能阻止进展期残疾进展。
- 促进髓鞘再生是神经保护策略,可恢复轴突传导和代谢支持。
- 动物研究提供干预靶点,但临床试验设计和结局测量仍需进一步工作。
核心结论
- 促进髓鞘再生是应对多发性硬化神经变性的策略,但有效疗法尚未就绪。
研究设计与样本
- 综述类文章,检索范围未报告。
主要发现
- 免疫治疗有效减少复发缓解期疾病活动及相关临床复发。
- 轴突和神经元损伤与丢失导致残疾进展,预防尚未实现且治疗具有挑战性。
- 动物研究提供了改善脑和脊髓髓鞘再生的干预靶点。
临床怎么用
- 髓鞘再生疗法尚未准备就绪,临床应关注免疫治疗控制疾病活动,同时关注进展期残疾管理。
局限性
- 临床试验设计及结局测量方法尚不明确,需进一步工作。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of multiple sclerosis has been transformed by the successful development of immunotherapies that efficiently reduce disease activity and related clinical relapses during the relapsing-remitting phase of the disease. However, the prevention of disability progression, which is due to axonal and neuronal damage and loss, has yet to be achieved and is therapeutically challenging, particularly during the progressive phase of the disease. One strategy to counteract neurodegeneration is to promote neuroprotection by enhancing myelin regeneration, hence restoring nerve conduction and metabolic support to the axon. Animal studies have provided targets for interventions to improve brain and spinal cord remyelination, paving the way for the translation of this research to humans. From these initial and promising forays, further problems have emerged, including questions on how best to design these clinical trials and appropriately measure the outcomes. Solving these problems will need additional work before efficacious pro-remyelination therapies will be ready for people with multiple sclerosis, but there is a real sense of hope that researchers are getting closer to a successful therapy.
引用
- Lubetzki C, Zalc B, Williams A, et al. Remyelination in multiple sclerosis: from basic science to clinical translation. Lancet Neurol. 2020. PMID: 32702337. doi:10.1016/S1474-4422(20)30140-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。